World's richest man ever existed on Earth was much wealthier than Mukesh Ambani, Adani, Musk, Ratan Tata, Gates combines; his name was…, travelled Mecca with gold worth…
While today's billionaires are breaking records, none have ever compared to the unimaginable wealth of Mansa Musa, a 14th-century king of the Mali Empire. He is known by most historians as 'the richest man of all time,' whose wealth would be about $500 billion (₹43.7 trillion) when calculated to current value. The only reason his wealth can even be estimated is that it was so vast and widespread that most historians believe there were no means of calculating it accurately. This makes him a financial imperishable legend, one that we won't come close to in the modern-day world of billionaires.
Mansa Musa ruled the Mali Empire between the years 1312 and 1337 CE. Under his reign, the Mali Empire attained perhaps its greatest fortune, becoming one of the wealthiest times and places in Africa. His wealth came in large part from the abundant gold and salt mines Mali possessed at this time. Mali was one of the world's primary sources gold at the time. As of that time, Mansa Musa also derived riches through the trade of ivory, slaves and any other valuable item he could sell; he built his empire to be one of the powers of Medieval world economy.'
Mansa Musa's enormous wealth was not the only reason for his legendary status—it was how he expressed that wealth that excited the world. In 1324, he undertook a famous pilgrimage to Mecca that would become a significant historical moment. From the accounts of him in the pamphlets that came to be written, Mansa Musa embarked on his pilgrimage with thousands of people of his royal entourage—people such as servants, soldiers, and in addition he brought with him dozens of camels, each laden with gold of about 136 kg. As he passed through cities like Cairo, he gave away enough gold as a donation to cause inflation in the cities and disrupted the economy for years. Mansa Musa's fame quickly spread, especially to the courts of kingdoms in Europe and Asia. Kings and emperors all over the world were eager to be in his good graces and wanted have an opportunity to receive a share of his wealth and massive generosity. Indeed, even after he died in 1337, stories would echo their way across continents of Mansa Musa, as the one of the richest men in the world.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
5 hours ago
- India.com
World's richest man ever existed on Earth was much wealthier than Mukesh Ambani, Adani, Musk, Ratan Tata, Gates combines; his name was…, travelled Mecca with gold worth…
While today's billionaires are breaking records, none have ever compared to the unimaginable wealth of Mansa Musa, a 14th-century king of the Mali Empire. He is known by most historians as 'the richest man of all time,' whose wealth would be about $500 billion (₹43.7 trillion) when calculated to current value. The only reason his wealth can even be estimated is that it was so vast and widespread that most historians believe there were no means of calculating it accurately. This makes him a financial imperishable legend, one that we won't come close to in the modern-day world of billionaires. Mansa Musa ruled the Mali Empire between the years 1312 and 1337 CE. Under his reign, the Mali Empire attained perhaps its greatest fortune, becoming one of the wealthiest times and places in Africa. His wealth came in large part from the abundant gold and salt mines Mali possessed at this time. Mali was one of the world's primary sources gold at the time. As of that time, Mansa Musa also derived riches through the trade of ivory, slaves and any other valuable item he could sell; he built his empire to be one of the powers of Medieval world economy.' Mansa Musa's enormous wealth was not the only reason for his legendary status—it was how he expressed that wealth that excited the world. In 1324, he undertook a famous pilgrimage to Mecca that would become a significant historical moment. From the accounts of him in the pamphlets that came to be written, Mansa Musa embarked on his pilgrimage with thousands of people of his royal entourage—people such as servants, soldiers, and in addition he brought with him dozens of camels, each laden with gold of about 136 kg. As he passed through cities like Cairo, he gave away enough gold as a donation to cause inflation in the cities and disrupted the economy for years. Mansa Musa's fame quickly spread, especially to the courts of kingdoms in Europe and Asia. Kings and emperors all over the world were eager to be in his good graces and wanted have an opportunity to receive a share of his wealth and massive generosity. Indeed, even after he died in 1337, stories would echo their way across continents of Mansa Musa, as the one of the richest men in the world.
Hans India
a day ago
- Hans India
ZeroHarm Eyes Rs 150 Crore Milestone by FY 2025 -'26, Accelerates Global Expansion into GCC
ZeroHarm Sciences, India's pioneering clean-label nutraceutical company, is set to accelerate its global footprint with a focused expansion into the GCC markets, including the UAE and the broader Middle East. Following a remarkable 10× revenue growth over the past two years and operating at a healthy ~20% EBITDA margin, the company closed the last fiscal year with 71 crore in gross revenue with an exit ARR of 90 crores. In the current fiscal, ZeroHarm is aiming for ₹150 crore in gross revenue, driven by strong domestic and global momentum and increasing traction in the United States, which now contributes nearly 30% of its overall revenue. At the heart of ZeroHarm's global success is its patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, dramatically enhancing their bioavailability by up to 5×, ensuring faster onset, precise dosing, and residue-free delivery. This breakthrough, backed by granted patents and deep R&D, makes ZeroHarm the first Indian company to bring pharmaceutical nanotech into nutraceuticals at scale. ZeroHarm's US FDA, CE, and ISO-certified formulations are backed by government-led clinical trials, with documented claims for 15 products, setting it apart in a market rife with unverified health claims. Today, the company offers over 70 targeted, condition-specific products spanning diabetes, arthritis, PCOS, liver and kidney health, immunity, and oncology support, with over million units sold across India to date. Backed by a fully owned, nanotech-enabled manufacturing facility, ZeroHarm can produce up to ₹250 crore worth of finished goods annually, making it one of the few Indian nutraceutical brands with true end-to-end production capabilities. To support its international expansion, ZeroHarm has acquired a dedicated manufacturing and R&D facility in the United States, enhancing local supply chain efficiency, fast-tracking formulation innovation, and enabling closer clinical and regulatory collaborations in key global markets. The U.S. infrastructure also gives ZeroHarm a significant strategic edge in developed markets, where stringent compliance standards often limit entry for Indian nutraceutical brands reliant on contract manufacturing. 'The global nutraceutical market is shifting, consumers are demanding not just clean labels, but clinical credibility. At ZeroHarm, we've combined deep R&D with pharma-grade nanotechnology to raise the bar for efficacy, safety, and transparency in preventive wellness. Our entry into the GCC is a natural extension of the trust we've built in India and the U.S., and a significant step toward making evidence-backed, plant-based therapeutics accessible to global consumers,' said Sachin Darbarwar, Founder & CEO, ZeroHarm Sciences. With distribution agreements and regulatory filings already underway, the company will also launch in the UK aside from the GCC markets by Q3 2025, introducing its clinically tested product lines via pharmacies, e-commerce platforms, and integrative practitioner networks.
Time of India
2 days ago
- Time of India
Romsons International: Pioneering Indian medical device manufacturing
The category winner of the ET MSME Awards 2024 has evolved from being a humble lab equipment maker in the 1950s to becoming an exporter par excellence. Here's a look at its journey. Tired of too many ads? Remove Ads Catheters, surgical gloves, and anaesthesia products Disposable syringes, IV cannulas, and infusion sets Mother and baby care products such as breast pumps and baby wipes Incontinence care products like adult diapers Diagnostic and monitoring devices, including glucometers and blood pressure monitors PPE kits and face masks Tired of too many ads? Remove Ads (This article is generated and published by ET Spotlight team. You can get in touch with them on etspotlight@ Manipal Hospitals, Fortis, Max Healthcare, Medanta, Apollo Hospitals. When your clients are some of India's most prestigious medical institutions, it's a given that you are at the forefront of healthcare International has pioneered medical device manufacturing in India since 1952. Established as 'Romsons Scientific and Surgical Industries' by Ram Lal Khanna in Amritsar, the company began with laboratory and scientific equipment before expanding into disposable medical equipment, producing its first non-sterile Nelaton catheter in 1967. This marked the beginning of Romsons' journey into the medical device 1994, the company founded Romsons International in Agra, a wholly export-oriented unit. The following years saw significant milestones, including ISO 9002:1994 certification in 1999 and CE mark accreditation, enabling exports to European countries. In 2003, Romsons achieved ISO 9001:2000 certification, and by 2007, it had also obtained ISO 13485:2003 certification, underscoring its commitment to quality and regulatory International has a portfolio exceeding 200 products across:Romsons' major international markets are the United States, United Kingdom, Vietnam, Maldives, Oman, and Bangladesh. It also participates in prestigious international trade fairs such as FIME in Miami, MEDICA in Germany, and Arab Health in Dubai. All in all, its distributor network is over 1,500-strong in more than 80 countries, which is no small feat: in FY24, export sales accounted for around 96% of company has earned numerous accolades for excellence, including awards from FICCI, CII, the Chamber of Commerce in India, and special recognition from the Ministry of MSME, Government of India. It won the Top Exporter of the Year (Manufacturing) category at the ET MSME Awards 2024, standing out from a pool of over 15,000 entries at India's largest, most credible MSME such as this exemplifies Romsons' leadership, and by extension, India's growing prowess in the global medical device industry. Through continuous innovation, adherence to stringent quality standards, and a robust global presence, Romsons has solidified its position as a trusted name in indigenous medical equipment more winner vignettes of the ET MSME Awards , keep an eye on this space.
